Zealand Pharma (DK)

Zealand Pharma is a public (ZEAL.CO) biopharmaceutical company based in Copenhagen, Denmark, specializing in the innovation and development of novel peptide drugs. All seven drug candidates in the pipeline, of which five are partnered, are identified through the company's own drug discovery activities. Zealand Pharma focuses on diabetes/metabolic diseases, gastrointestinal diseases and cardiovascular disorders. The company has a strong franchise in diabetes including partnership agreements with two world-leading diabetes companies, Sanofi and Boehringer Ingelheim. The lead product is lixisenatide, a once-daily GLP-1 agonist licensed to Sanofi for the treatment of Type 2 diabetes, in registration phase.